Endocrine therapy de-escalation a possibility for ER-low positive breast cancer

medwireNews: Women with estrogen receptor (ER)-low positive breast cancer may be considered for 2 to 3¬†years of endocrine therapy rather than the standard 5¬†years without a negative impact on disease-free…

A $1.57 million grant funds breakthrough breast cancer prevention and treatment research

Mason researcher Milton Brown is one of only a handful of physician scientists in the United States that holds a PhD in synthetic chemistry and a medical degree. Photo by…

FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer

By The ASCO Post Staff Posted: 3/14/2022 10:51:00 AM Last Updated: 3/15/2022 8:32:00 AM On March 11, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for the adjuvant…

Olaparib in gBRCA+ Breast Cancer; ‘Clearly Practice Changing’

Adjuvant olaparib (Lynparza) significantly improves overall survival (OS), compared with placebo, for patients with high-risk, early-stage, HER2-negative, germline BRCA-mutated breast cancer, according to the latest results from the pivotal phase…

Short-Term Endocrine Therapy Effective in ER-Low Positive Breast Cancer

Disease-free survival (DFS) in patients with estrogen receptor (ER)-low positive breast cancer who received endocrine therapy for 2 to 3 years was similar to DFS in patients who received endocrine…

Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022

— Blueprint Medicines to host investor conference call and webcast on Friday, April 8, 2022 — CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today announced…